We are in the midst of an epidemic of metabolic diseases such as obesity and diabetes, so a better understanding of the basic pathways of energy homeostasis is critical to the development of new medical therapies. Previous studies, including work funded under this grant, have shown that the PGC1 coactivators are major regulators of energy metabolism in mammalian systems. PGC1a regulates mitochondrial biogenesis and oxidative metabolism in many tissues, and links these genetic programs to the external environment. PGC1a controls important metabolic programs in the liver, brown fat, heart and skeletal muscle. In skeletal muscle, the PGC1a gene is induced during many kinds of exercise in mice and humans, and drives programs of mitochondrial biogenesis, fiber-type switching and resistance to atrophy/dystrophy. Most recently, we have shown that PGC1a initiates a novel program of angiogenesis that is potent and independent of the canonical HIF angiogenesis pathway. In preliminary data for this proposal, we show that the PGC1a gene gives rise to several novel proteins in muscle via alternative splicing. The original PGC1a (now called PGC1a1) and a new shorter form (termed PGC1a4) are both highly induced during exercise in mice. When expressed in primary culture or in vivo, PGC1a4 induced muscle cell hypertrophy but not mitochondrial biogenesis. This hypertrophy is associated with regulation of several genes of the myostatin and IGF1 pathways, both key signaling transduction systems of muscle growth.
Our first Aim will test the hypothesis that PGC1a4 plays an important role in regulating physiological muscle hypertrophy and metabolic disease in vivo. To do this, we will create transgenic models of having both gain and loss of function of PGC1a4 in mice. We will combine these with different experimental models of muscle hypertrophy, atrophy and metabolic disease, including diet and age-induced obesity and diabetes.
Our second Aim will investigate the mechanisms by which PGC1a4 can effect these changes in muscle cell growth and function. We will focus initially on the hypothesis that PGC1a4 works through the IGF1 and myostatin systems, since genes of these pathways are both robustly regulated by PGC1a4. Our last Aim will focus on the interaction between PGC1a1 and AMP kinase. We have created a murine strain with mutations in the AMPK sites in PGC1a1, and we will now critically test the hypothesis that this functional interaction contributes to the metabolic actions of both molecules in skeletal muscle and liver. Together, these studies promise to elucidate a major new pathway controlling skeletal muscle hypertrophy and muscle function. This has a direct impact on our ability to understand and provide new therapies in important diseases of aging, muscular dystrophies and obesity/diabetes.

Public Health Relevance

This project proposes work that could be useful for developing new therapies for diabetes, muscle loss in aging and muscular dystrophies. We have discovered a new form of a molecule called PGC1?4 that is increased in exercise and causes muscle cell growth and muscle fiber growth in vivo. Learning how to control PGC1?4 production may lead to improved treatments for these human diseases.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01DK061562-13
Application #
8668034
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Laughlin, Maren R
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
White, James P; Wrann, Christiane D; Rao, Rajesh R et al. (2014) G protein-coupled receptor 56 regulates mechanical overload-induced muscle hypertrophy. Proc Natl Acad Sci U S A 111:15756-61
Rao, Rajesh R; Long, Jonathan Z; White, James P et al. (2014) Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 157:1279-91
Lustig, Yaniv; Ruas, Jorge L; Estall, Jennifer L et al. (2011) Separation of the gluconeogenic and mitochondrial functions of PGC-1{alpha} through S6 kinase. Genes Dev 25:1232-44
Wu, Jun; Ruas, Jorge L; Estall, Jennifer L et al. (2011) The unfolded protein response mediates adaptation to exercise in skeletal muscle through a PGC-1?/ATF6? complex. Cell Metab 13:160-9
Devarakonda, Srikripa; Gupta, Kushol; Chalmers, Michael J et al. (2011) Disorder-to-order transition underlies the structural basis for the assembly of a transcriptionally active PGC-1*/ERRýý complex. Proc Natl Acad Sci U S A 108:18678-83
Wenz, Tina; Rossi, Susana G; Rotundo, Richard L et al. (2009) Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A 106:20405-10
Estall, Jennifer L; Ruas, Jorge L; Choi, Cheol Soo et al. (2009) PGC-1alpha negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb(alpha) axis. Proc Natl Acad Sci U S A 106:22510-5
Estall, Jennifer L; Kahn, Mario; Cooper, Marcus P et al. (2009) Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes 58:1499-508
Cooper, Marcus P; Uldry, Marc; Kajimura, Shingo et al. (2008) Modulation of PGC-1 coactivator pathways in brown fat differentiation through LRP130. J Biol Chem 283:31960-7
Arany, Zoltan; Wagner, Bridget K; Ma, Yanhong et al. (2008) Gene expression-based screening identifies microtubule inhibitors as inducers of PGC-1alpha and oxidative phosphorylation. Proc Natl Acad Sci U S A 105:4721-6

Showing the most recent 10 out of 30 publications